20-Feb-2026
CDC said to delay vaccine panel meeting after lawsuit challenging its composition
Seeking Alpha News (Thu, 19-Feb 2:10 PM ET)
Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
PRNewswire (Thu, 19-Feb 8:00 AM ET)
Market Chameleon (Wed, 21-Jan 6:44 AM ET)
Novavax Announces Entering into a License Agreement with Pfizer
PRNewswire (Tue, 20-Jan 7:15 AM ET)
Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference
PRNewswire (Wed, 7-Jan 8:00 AM ET)
Novavax Highlights R&D Strategy with Fireside Chat at Jefferies London Healthcare Conference
Market Chameleon (Wed, 12-Nov 3:56 AM ET)
Novavax Unlocks $60 Million and Targets $230 Million in Future Savings With Major Site Consolidation
Market Chameleon (Wed, 22-Oct 4:25 AM ET)
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Novavax trades on the NASDAQ stock market under the symbol NVAX.
As of February 20, 2026, NVAX stock price declined to $9.20 with 3,141,559 million shares trading.
NVAX has a beta of 1.46, meaning it tends to be more sensitive to market movements. NVAX has a correlation of 0.18 to the broad based SPY ETF.
NVAX has a market cap of $1.49 billion. This is considered a Small Cap stock.
Last quarter Novavax reported $70 million in Revenue and -$.48 earnings per share. This beat revenue expectation by $28 million and exceeded earnings estimates by $.48.
In the last 3 years, NVAX traded as high as $23.86 and as low as $3.53.
The top ETF exchange traded funds that NVAX belongs to (by Net Assets): XBI, VTI, IWM, VB, VXF.
NVAX has outperformed the market in the last year with a price return of +16.2% while the SPY ETF gained +14.1%. NVAX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +47.9% and +11.5%, respectively, while the SPY returned +6.0% and -0.2%, respectively.
NVAX support price is $8.84 and resistance is $9.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVAX shares will trade within this expected range on the day.